Karyopharm Therapeutics (KPTI) Projected to Release Earnings on Monday

Karyopharm Therapeutics (NASDAQ:KPTI) is expected to be announcing its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect Karyopharm Therapeutics to post earnings of ($0.9460) per share and revenue of $33.54 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:00 AM ET.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($1.37) by ($0.95). The company had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $32.19 million. On average, analysts expect Karyopharm Therapeutics to post ($4.70) EPS for the current fiscal year and ($2.33) EPS for the next fiscal year.

Karyopharm Therapeutics Stock Performance

NASDAQ KPTI opened at $0.66 on Friday. The business has a fifty day moving average price of $1.22 and a 200 day moving average price of $6.02. The company has a market cap of $15.01 million, a P/E ratio of -0.05 and a beta of 1.04. Karyopharm Therapeutics has a one year low of $0.31 and a one year high of $10.99.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on KPTI shares. HC Wainwright lowered shares of Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a report on Friday, July 31st. Royal Bank Of Canada reissued an “outperform” rating and issued a $16.00 price target on shares of Karyopharm Therapeutics in a research note on Tuesday, July 21st. Weiss Ratings downgraded shares of Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. Wall Street Zen lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Robert W. Baird cut shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $11.50.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company’s research centers on selective inhibitors of nuclear export (SINE), a class of compounds designed to interfere with the transport of tumor-suppressing proteins and other molecules in cancer cells.

Karyopharm’s leading product is selinexor, marketed in the United States as XPOVIO and in certain international markets as NEXPOVIO.